Upon confirmation of your eligibility to participate in the OPUS clinical study, you will receive cenerimod or a placebo depending on which group you get assigned to after randomization. Regardless of whether you receive cenerimod or a placebo, you will continue to receive your current SLE treatment. You will also have regular health assessments by your medical team including close monitoring and immediate support while you participate in the OPUS clinical study.
Philippines 
日本語 